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Summary: 
Objectives: Since early etiologic identification is critical to select appropriate specific 
status epilepticus management, we aim to validate a clinical tool we developed that 
uses history and readily available investigations to guide prompt etiologic 
assessment.   
Methods: This prospective multi-center study included all adult patients treated for 
SE of all but anoxic causes from four academic centers. The proposed tool is 
designed as a checklist covering frequent precipitating factors for SE. The study 
team completed the checklist at the time the patient was identified by EEG request. 
Only information available in the emergency department or at the time of in-hospital 
SE identification was used. Concordance between the etiology indicated by the tool 
and the determined etiology at hospital discharge was analyzed, together with inter-
rater agreement. 
Results: 212 patients were included. Concordance between the etiology hypothesis 
generated using the tool and the finally determined etiology was 88.7% (95% CI: 86.4 
– 89.8) (kappa = 0.88). Inter-rater agreement was 83.3% (95% CI: 80.4 – 96) (kappa 
= 0.81). 
Significance: This tool is valid and reliable to identify early the etiology of a SE. 
Physicians managing patients in SE may benefit from using it to identify promptly the 
underlying etiology, thus facilitating selection of the appropriate treatment. 
 
Key words: Epilepsy; diagnostic test assessment; critical care; coma; neurologic 
emergency 
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Introduction: 
With an annual incidence of 10–40 per 100,000 person years and a mortality 
between 7% - 33% 1, 2, 3 status epilepticus (SE) is one of the most frequent 
neurological emergencies. Several independent predictors of poor outcome have 
been identified, including advanced age, de novo presentation, impairment of 
consciousness before treatment, and seizure type, but the most critical factor by far 
is the underlying etiology 4, 5, 6, 7. Although much attention has been paid to seizure 
cessation with administration of anti-seizure drugs (ASDs) 8, 9, it is far more critical to 
rapidly identify and target a treatable underlying etiology9. Indeed, some etiologies 
such as cerebrovascular events, severe metabolic disturbances, alcohol withdrawal 
or intoxication, brain tumor related events and infections need emergent and specific 
treatments beyond ASDs. Earlier identification of the SE etiology would enhance 
rapid and more focused treatment, and potentially improve outcome.  
Due to the diversity of possible etiology10, this is potentially a puzzling process in 
acute and emergent situation for a clinician unfamiliar with SE, particularly outside of 
a tertiary care facility. Clinical decision supporting tools may help clinicians to gather 
important data for the decision-making process, and guide medical management 
more effectively, thus reducing practice errors and costs 11. These tools are widely 
available in many other clinical settings, and notably for other acute conditions for 
which rapid identification of the underlying etiology is fundamental, such as chest 
pain 12 or acute headache 13.  
In order to assist a clinician to rapidly identify an underlying etiology, we developed a 
user-friendly tool labeled Status Epilepticus Etiology Identification Tool (SEEIT) 
utilizing elements of the clinical history and routinely available laboratory 
investigations that can be used at the bedside in the Emergency Department (ED) or 
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the intensive care unit (ICU) to streamline the evaluation into etiology. We performed 
a multi-center prospective observational study in order to determine the validity and 
reliability of this tool. 
Methods: 
• Primary research question: 
The primary research question was to evaluate the validity and reliability of the 
SEEIT by assessing its propensity to identify the correct etiology and its inter-
rater agreement.  
• Standard Protocol Approvals, Registrations, and Patient Consents: 
The Institutional Review Boards of each center approved this study. As this 
observational study involved no risk for patients and focused on acute phase 
of critically ill patients, consent was waived. 
• Cohort and SE definition: 
In this observational study, we prospectively identified every consecutive adult 
patient (age >16 years) with SE admitted to four university hospitals, from 
February 1st 2013 at the Centre Hospitalier Universitaire Vaudois (CHUV), 
Lausanne, Switzerland; from June 1st 2013 at the Brigham and Women’s 
Hospital (BWH) and the Massachusetts General Hospital (MGH), Boston, 
USA; and from November 1st 2013 at the Beth Israel Deaconess Medical 
Center (BIDMC), Boston, USA. The inclusion period ended on February 28th 
2014.. All patients with suspected SE at each institution have 
electroencephalograms (EEGs) within 24 hours, so subjects were screened 
through review of all EEGs ordered during that period. SE was defined as the 
occurrence of ongoing epileptic or repeated epileptic seizures without full 
recovery lasting more than 5 min 9. EEG diagnosis was required for non-
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convulsive SE, as recently described 14. This cohort includes patients admitted 
for SE and also patients developing SE during the hospital stay, but patients 
with post-anoxic SE were excluded.  
• Definition of variables 
Demographic data recorded included: 1) age, 2) gender; 3) worst seizure type 
categorized as focal seizures without impairment of consciousness, focal 
seizures with impairment of consciousness, generalized convulsions, absence 
seizures, myoclonic seizures 15 and non-convulsive SE in coma (NCSEC); 4) 
level of consciousness before treatment was categorized as follows: alert, 
confused, somnolent (arousable with clear contact), stuporous (arousable 
without contact) and comatose. The STatus Epilepticus Severity Score 
(STESS) was calculated for every patient using age, seizure type, level of 
consciousness and history of previous seizures 16. The timing of onset of the 
SE was determined as precisely as possible using pre-hospital chart and 
emergency department summaries. For SE episodes without clear onsets 
(unwitnessed, subtle non-convulsive SE), we considered the last observed 
time of good health as the beginning of the SE. Each ASD treatment was 
recorded prospectively, but treatments modified or initiated after control of 
seizures were not evaluated. Refractory SE was defined as failure to respond 
to an adequate dose of an initial benzodiazepine followed by a second-line of 
a non-sedating ASD 9. The end of the SE episode was defined by the last 
clinical or electrical seizure without recurrence for at least 48 hours, off 
sedation.  
The etiology of each SE episode was described in free text based on medical 
charts and then assigned to the nineteen categories listed in Table 1.  
  
Alvarez, 6 
Outcome at discharge was categorized as return to pre-morbid baseline, new 
morbidity or death.  
• Status Epilepticus Etiology Identification Tool (SEEIT) description and 
evaluation 
The proposed tool, shown in Figure 1, was developed by two of the authors 
(VA and AOR) based on the list of the potential underlying etiology included in 
the current SE guidelines 9 and adapted based on their clinical experience. 
After its completion, it was reviewed by two others authors, experts in the field 
(JWL and FWD). Hypertensive encephalopathy was not included in the tool: 
since hypertension is frequently seen secondary to the acute brain injury, too 
much emphasis on hypertension in the acute setting could be misleading. 
Moreover hypertensive encephalopathy is not a frequent cause of SE 10,17.  
The tool is designed as a checklist including 4 main parts and several 
subsequent questions. The first part aims to confirm the diagnosis of SE 
(fulfilling the operational definition) 18 and also raises the question of 
psychogenic non-epileptic status epilepticus (PNESE), which can be mistaken 
for refractory SE 19. The tool then discriminates between SE in the setting of 
known epilepsy or a structural brain disorder vs. occurring without any known 
brain pathology. For each of these parts, the tool includes questions about 
common treatable etiologies. Finally, the fourth part emphasizes signs 
suggestive of a CNS infection and includes cerebrospinal fluid (CSF) findings 
if a lumbar puncture is performed. At the end of the assessment, the rater is 
invited to record the suspected etiology as free text based on the assessment 
directed by the SEEIT. The tool also includes the list of investigations required 
by current guidelines for SE evaluation 9. The etiology is eventually placed into 
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one of the 19 categories (see Table 1) to enable evaluating concordance with 
the definitive etiology determined at the end of the hospital stay. Of note, for 
the concordance evaluation, when an acute precipitating factor occurred in the 
context of a remote brain injury, the “acute” condition was considered 
predominant, as the tool aims to identify acute treatable conditions. 
The SEEIT was completed for every patient at the time of identification by the 
study team -- based only on the information available in the ED or at the time 
of in-hospital SE identification and before discharge summary diagnosis was 
available. The first author (VA) completed the SEEIT for the three centers 
involved in Boston, USA (BWH, MGH, BIDMC) and the EEG attending filled 
the assessment under the same conditions for the patients in the CHUV, 
Lausanne, Switzerland.  
Because the SEEIT was designed to be used by non-specialist physicians and 
was also completed by neurologists with specialty training in epilepsy, an 
inter-rater evaluation between one of the investigators (VA) and an emergency 
physician (fourth year Emergency resident at BWH) (DC) was performed for 
the first 30 cases of SE treated at BWH.  To reflect the “real-life” use of the 
tool, the ED physician did not receive any training in use of the SEEIT. 
• Statistical analysis 
Inter-rater evaluation between VA and DC, and concordance between the 
etiologies generated by the SEEIT and the etiology finally determined during 
the hospitalization, were evaluated with Cohen’s kappa coefficient. In order to 
identify any misleading factors for correct early etiology identification, patients 
with correct and incorrect etiologies generated using the SEEIT were 
compared using χ2, ANOVA and Wilcoxon rank-sum test, as required. 
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Significance was assumed with p < 0.05.  Data were analyzed using Stata 
11.1 (StataCorp, College Station, Texas, USA). 
 
Results: 
The Figure 2 outlines the study profile. A total of 212 consecutive patients were 
included in the study. Demographics and SE characteristics are summarized in Table 
2. Gender was evenly distributed; the median age was 60 years old (range: 18-93). 
Premorbid seizures occurred in 49.1% patients. About half of the subjects had 
generalized convulsive seizures, followed by 28.9% with focal seizures with 
consciousness impairment, 15% with focal seizures without impairment of 
consciousness, and 8% with NCSEC. Absence and myoclonic status were 
infrequent, 1.42% and 0.5% respectively. Consciousness was impaired in most, with 
17% of patients presenting as “comatose” and 41.5% “stuporous”. The mean STESS 
was 2.64 (SD: 1.63) and around half of patients suffered from refractory SE. A 
median of 3 ASDs (range: 0-13) was used and 11.3% underwent intubation as part of 
a SE treatment protocol. The mortality rate was 12.8%, while 45.3% of patients 
returned to their premorbid clinical baseline at discharge. 
In addition to the 212 patients in SE, two had EEGs for SE but were eventually found 
to have PNESE. Both were treated acutely as refractory SE. One was intubated for 
“convulsion control.” Of note, in the patients’ charts, there were descriptions of the 
events including features such as “waxing-and-waning” symptoms “stopped by 
suggestion” for the first patient; and “waxing and waning” and “pelvic thrusting 
movements” for the second. The SEEIT-generated etiology was correct for these two 
events. 
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The definitive etiologies at hospital discharge are listed in Table 1. ASD related 
causes (non-adherence, iatrogenic withdrawal, sub therapeutic level) were the most 
frequent, occurring in 16.3%, followed by brain tumor (without acute change in the 
tumor) in 13.2%. The “unclassified” category included 3 cases of multiple sclerosis, 2 
confirmed and 1 possible posterior reversible encephalopathy syndrome (PRES), 2 
neoplastic meningitis, and single cases of NMDA encephalitis, neurosarcoidosis, 
eclampsia, arterio-venous malformation without bleeding, and microangiopathic 
hemolytic anemia. A need for specific etiologic treatment in addition to ASDs was 
considered necessary in 90 of 212 patients (42.45%). 
The etiology identified early using the SEEIT was correct in 188 patients (88.7%) 
(95% CI: 86.4 – 89.8) with a kappa coefficient of 0.88. There was inter-rater 
agreement in 83.3% (95% CI: 80.4 – 96) of cases between VA and the DC, with a 
kappa coefficient of 0.81. 
A further analysis comparing features of patients with a correct SEEIT-generated 
etiology versus an incorrect one did not show any significant differences regarding 
age (p=0.95), gender (p=0.08), participating center (p=0.81), type of seizure 
(p=0.81), level of consciousness (p=0.94), time to treatment (p=0.36), or refractory 
SE (p=0.50). Only the absence of previously known seizures was associated with a 
higher risk of incorrect early etiology identification. A total of 103 of the 188 patients 
with an etiology correctly determined by the SEEIT had a history of earlier seizures 
(54.8%), whereas this was the case in only 5 of 24 patients with an incorrectly 
SEEIT-determined etiology (20.8%) (p=0.002, χ2).  
Table 3 provides a detailed description of the 24 cases in which the etiology 
generated using the tool was incorrect. Seven (29.2%) were misdiagnosed due to 
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information missed on early imaging, five (20.8%) due to CSF misinterpretation, three 
(12.5%) to incomplete history, and three (12.5%) presentations were probably too 
complex to be diagnosed accurately in the ED setting (1 NMDA-encephalitis, one 
with microangiopathic hemolytic anemia, and one with toxoplasmosis).  In two 
patients (8.4%), known remote conditions were incorrectly assumed to be the 
etiology when others factors were actually responsible.  One misdiagnosis (4.2%) 
was due to misinterpretation of a systemic inflammatory response syndrome (SIRS). 
Finally, three (12.5 %) were misdiagnosed due to disagreement on causality 
judgment of minor precipitants between the tool rater and the hospital discharge 
summary.  
Discussion: 
The principal finding of this study is that early identification of the underlying etiology 
for SE is possible using a tool designed to guide differential diagnosis assessment. 
The SEEIT appears valid, with concordance in 88.7% of cases between the etiology 
hypothesis generated using SEEIT and the definitive etiology determined at hospital 
discharge. It is also reliable, with a high inter-rater agreement between physicians of 
different subspecialties and levels (ED resident and trained neurologist). 
Consequently, the SEEIT may be of assistance to non-specialist physicians in 
guiding their identification of the etiology of SE promptly and expeditiously.  
This early identification of SE etiology is important, as in this cohort nearly half of 
patients warranted a specific treatment of the illness causing their SE, along with 
ASD treatment. Further, because etiology is one the most important determinants of 
SE outcome 4, 5, 10, 20, an etiology-tailored treatment should be initiated as early as 
possible, particularly in conditions such as CNS infection, sepsis, metabolic 
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disturbances, or acute cerebrovascular illnesses. This tool may be valuable in 
prompting clinicians to think earlier about etiology-guided treatment.  Trying to 
improve ASD protocols and refining them may have a limited impact on SE outcome. 
Indeed, protocol adherence 21 and newer ASDs do not appear to affect prognosis 22  
while intramuscular treatment 23 and prehospital protocols 24 already allow very rapid 
ASD administrations. Therefore, alternatives to ASD trials should be explored to 
improve outcome of patients suffering from SE. Efforts aimed at identifying and 
targeting the underlying biological background could be one option 10, 25.  
A further relevant finding is that two patients presenting with PNESE signs noted in 
the first part of the SEEIT were treated as having refractory SE, possibly because of 
lack of awareness of PNESE symptoms in the ED; one was even intubated. Indeed, 
these episodes are frequently misdiagnosed as “refractory SE” 19 and poor outcome 
due to overtreatment has been reported 26. By highlighting some clinical features of 
PNESE, the SEEIT may help avoid unnecessary, and potentially harmful, treatment 
in these occasions. Of note, the rate of PNESE mistaken for SE is low in this cohort. 
This is likely explained by the tertiary care setting and the 24/7 availability of 
neurology consultants in the four centers involved in this study. 
We were unable to demonstrate any significant factors that interfered with correct 
etiology identification using our tool, other than presence of prior seizures. This may 
reflect the fact that medication non-adherence or recent treatment adjustments are 
common SE causes and are easy to recognize. This reinforces the principle that all 
patients with SE should be evaluated carefully to identify the underlying etiology, 
independently of age, seizure type, or SE severity. 
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The detailed description of misdiagnosed cases (Table 3) shows that brain MRI is 
crucial if history and CT scan fail to identify the etiology; in another smaller study, 
MRI improved the diagnosis by 32% in a cohort of 34 patients 27. CSF data may be 
misleading. Some cases of SE were incorrectly labeled as due to infectious 
processes because of the CSF pleocytosis -- which turned out to be non-infectious 
(due to neoplasic or auto-immune conditions) or due to the SE itself in one case of 
mild pleocytosis, which can be seen in 10% of SE occurring in the setting of a known 
epilepsy 28. Nevertheless, because the exact cause of CSF pleocytosis may take 
several days to be clarified, and in view of the potential poor outcome associated with 
CNS infections, it is still reasonable to consider all SE with pleocytosis as infectious 
until proven otherwise.  This study also included a 75-year-old man with new onset 
refractory SE associated with fever and a normal CSF study (4 white cells) performed 
36 hours after symptom onset his and CSF PCR showed HSV 1 encephalitis. CSF is 
abnormal in 95% of HSV1 encephalitis 29, but can be normal early in the illness 30, as 
illustrated by this case. This particular pitfall is pointed out in the SEEIT tool.  
As reported earlier 31, 32, subtherapeutic ASD levels due to non-adherence or 
treatment adjustment are among the most frequent causes of SE. This should be 
addressed carefully by a thorough history, and ASD levels should be obtained when 
appropriate. Because some newer ASD levels cannot be measured quickly, detecting 
non-adherence based on this feature alone can be difficult. A careful history with 
relatives is thus very important in such cases. The relatively high incidence of SE due 
to brain tumors in this cohort, as opposed to previous studies 31, 33 is likely due to a 
referral bias, as the four institutions in this study have, or are closely associated with, 
large neuro-oncology clinics. Similarly, while alcohol withdrawal was a frequent 
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precipitant in other series, ranging from 13% 32 to 17% 31 it was infrequent in ours 
(2.8%), also probably explained by a referral bias.   
The strength of this study is the large number of patients from four international sites 
and the prospective evaluation implying a good potential for generalization and good 
data quality. The main limitation is that the SEEIT was completed by the study 
investigator familiar with it (a neurologist) and not by the treating physician. This 
could help to explain the high concordance coefficient between the SEEIT and the 
etiology determined after a comprehensive evaluation. Still, the inter-rater agreement 
evaluation between the study investigator and an emergency physician was high, 
and there was no difference in the agreement rate among the four centers involved. 
Another limitation is that the SEEIT relies on history for some items and sometimes 
there are neither relatives nor witnesses. A comprehensive history is a key 
component in the management of many conditions, including SE, and unfortunately, 
our tool cannot fill the lack of information in these situations. Moreover, as patients 
were screened by using the EEG request (and not in the ED), we could not exclude 
the possibility that some information available in the EEG laboratory influenced the 
investigator completing the tool, but only information available during the ED stay 
was used for the early etiology assessment. Also, we cannot exclude that due to the 
EEG screening process, some brief or unrecognized SE episodes were missed. 
Indeed, in these situations, treating physician might not have requested an EEG.  
Also, the yield of each item in the SEEIT was not evaluated, but in clinical practice, a 
diagnosis is made after a global assessment and not based on one particular feature 
alone. Another shortcoming is that the SEEIT failed to identify definite etiology 
correctly because sometimes history, imaging or some data were not available. The 
results would perhaps have been different if all information were available in each 
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case. However, in that case, this would probably have increased the performance of 
SEEIT. The tertiary hospital setting may also confer a selection bias. Indeed, this 
may have resulted in the inclusion of more patients with severe SE. We do not 
believe that this should influence the validity of the SEEIT.  Moreover, fewer patients 
were enrolled at the MGH than at the BWH. We cannot exclude the possibility of 
under sampling at the MGH and do not expect this to have influenced our findings. 
Finally, we used broad inclusion criteria: all types of SE, and an operational definition 
9, as opposed to more rigorous inclusion criteria focusing on generalized convulsive 
SE lasting more than 30 minutes. As the SEEIT is designed to be used in daily 
practice, these inclusion criteria may better reflect “actual clinical practice". 
This study shows that the SEEIT correctly identify the cause of a SE in 88.7%. It also 
demonstrates that it is possible to identify the etiology of an episode of SE early with 
a valid and reliable clinical tool to guide differential diagnosis, used by physicians 
from different subspecialties. Further studies are needed to evaluate whether the 
SEEIT will improve decision-making process in SE management, avoiding 
unnecessary investigations or treatments, influencing the length of stay, or impacting 
on clinical outcome.  
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Tables and Figures:  
 
Table 1: List of diagnostic categories and their frequencies as definitive SE etiology 
Total,	n=212	 n	 %	
ASD	related	(non-adherence,	recent	change	or	low	
levels)	
34	 16.04	
Brain	tumor	without	acute	change	(no	change	or	
increase	in	tumor	load)	
28	 13.21	
Acute	hemorrhagic	cerebrovascular	event	 21	 9.91	
Known	epilepsy	(non-structural)	without	provocative	
factors	(breakthrough	seizures)	
16	 7.55	
Remote	ischemic	cerebrovascular	event	 14	 6.6	
Unclassified*	 13	 6.13	
CNS	infection	(meningitis	or	encephalitis)	 12	 5.66	
Unknown	origin	 11	 5.19	
Toxic-metabolic	 10	 4.72	
Systemic	infection	/	sepsis	 10	 4.72	
Remote	hemorrhagic	cerebrovascular	event	 8	 3.77	
Acute	TBI	 7	 3.3	
Acute	ischemic	cerebrovascular	event	 5	 2.36	
Remote	TBI	 6	 2.83	
Alcohol	related	(withdrawal	or	intoxication)		 6	 2.83	
Brain	tumor	with	acute	change	(bleeding,	recent	
biopsy/surgery	or	rapid	increase	in	edema)	
5	 2.36	
Benzodiazepine	withdrawal	 4	 1.89	
Neurodegenerative	disease	 2	 0.94	
Other	drugs	known	to	reduce	seizure	threshold		 0	 0	
Abbreviations: ASD = anti-seizure drug, CNS = central nervous system, TBI = traumatic brain injury 
*: Unclassified includes: 3 multiple sclerosis, 2 confirmed and 1 possible posterior reversible encephalopathy 
syndrome (PRES), 2 tumoral meningitis, 1 NMDA encephalitis, 1 neurosacroidosis, 1 eclampsia, 1 arteriovenous 
malformation without bleeding and 1 cases of microangiopathic hemolytic anemia 
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Table 2: Cohort description 
Patients	(n=212):	 	 	
Demographics:	 	 	
Age	(median,	range)	 60	 18-93	
Male	(n,%)	 106	 50	
History	of	previous	seizures	(n,%)	 104	 49.1	
Center	(n,%)	 	 	
CHUV	 104	 49.1	
BWH	 65	 30.7	
MGH	 30	 14.2	
BIDMC	 13	 6.1	
SE	characteristics	 	 	
Worst	seizure	type	(n,%)	 	 	
Focal	without	consciousness	impairment	 32	 15.1	
Focal	with	consciousness	impairment	 57	 28.9	
Absence		 3	 1.42	
Myoclonic	 1	 0.5	
Generalized	convulsive	 102	 48.1	
Non-convulsive	SE	in	coma	 17	 8	
Level	of	consciousness	before	treatment	(n,%)	 	 	
Alert	 24	 11.3	
Confused	 51	 24.1	
Somnolent	 13	 6.1	
Stuporous	 88	 41.5	
Comatose	 36	 17	
STESS	(mean,	SD)	 2.64	 1.63	
Refractory	SE	(n,%)	 119	 56.12	
Number	of	different	ASD	used	(median,	range)	 3	 0	-	13	
Coma	induction	for	SE	control	(n,%)	 24	 11.3	
Outcome	at	discharge	(n,%)	 	 	
Return	to	clinical	premorbid	baseline	 96	 45.3	
New	morbidity	 89	 42	
Death	 27	 12.8	
Abbreviations: ASD = anti-seizure drug; BWH= Brigham and Women’s Hospital; BIDMC = Beth Israel Deaconess 
Medical Center; CHUV = Centre Hospitalier Universitaire Vaudois; MGH= Massachusetts General Hospital; 
STESS = Status Epilepticus Severity Score. 
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Table 3: Details of patient for which the early suspected etiology using the SEEIT was incorrect. 
Pt	 Age	 Gender	 Previous	
seizures	
Etiology	generated	
using	the	SEEIT	
Final	etiology	 Case	description	 Explanation	
1	 54	 F	 No	 Cryptogenic	 Brain	Glioma	 Small	temporal	glioma	was	missed	in	the	CT	performed	in	ED,	but	seen	on	
MRI	later.	Of	note,	because	seizures	were	focal,	the	tool	advised	an	MRI.	
Etiology	missed	on	CT	
2	 76	 M	 No	 Cryptogenic	/	
encephalitis?	
Brain	Glioma	 Because	of	new	onset	refractory	epilepsy	with	normal	CT	and	normal	CSF	
analysis,	SEEIT	evoked	a	cryptogenic	SE	or	encephalitis	in	early	phase	/	
autoimmune	process.	The	later	MRI	revealed	a	glioma.	
Etiology	missed	on	CT	
3	 40	 F	 Yes	 Drugs	related	
(ciprofloxacine)	
Known	epilepsy	without	
provocative	factors	
Patient	with	known	epilepsy	experienced	SE	in	the	context	of	ciprofloxacine	
prescribed	for	UTI	without	systemic	involvement.	The	discharge	summary	
did	not	retain	ciprofloxacine	as	provocative	factor.	
Disagreement	on	causality	
judgment	of	minor	
precipitants	
4	 57	 F	 No	 Meningo-encephalitis	
(infectious)	
Carcinomatous	
leptomeningitis	
SE	after	lumbar	surgery	for	vertebral	metastasis	(breast	cancer).	CSF	showed	
a	pleocytosis	(115	white	cells/mm3).	Infectious	meningitis	was	proposed	by	
the	SEEIT.	Further	CSF	analysis	revealed	metastatic	cells.	
CSF	data	misinterpreted	
5	 21	 F	 No	 Meningo-encephalitis	
(infectious)	
NMDA	encephalitis	 Presented	with	refractory	SE	and	mild	CSF	pleocytosis.	Possible	CNS	
infectious	was	retained	using	the	SEEIT.	Further	analysis	didn't	find	any	
infectious	agent	and	revealed	NMDA	anti-bodies.	
Failure	to	identify	a	
complex	disease	in	the	
emergency	setting	
6	 72	 M	 No	 Remote	ischemic	
stroke	
Lymphomatous	meningitis	 Known	for	Waldenstrom	disease.	Initial	imaging	showed	an	old	previously	
asymptomatic	stroke	retained	as	responsible	using	the	SEEIT.	LP	done	
because	of	unexpected	evolution	revealed	lymphomatous	meningitis.	
Remote	brain	pathology	
incorrectly	retained	
7	 19	 F	 Yes	 Known	epilepsy	
without	provocative	
factors	
Cryptogenic	 History	revealed	a	couple	febrile	seizures	during	childhood	and	no	other	
explanation.	Because	of	the	very	long	time	before	recurrence	of	seizure,	she	
was	not	considered	as	having	epilepsy	before	the	SE	episode	and	thus	
considered	as	cryptogenic.	
Disagreement	on	causality	
judgment	of	minor	
precipitants	
8	 71	 F	 No	 Drug	related	
(clozapine)	
Posterior	reversible	
encephalopathy	syndrome	
(PRES)	
In	the	context	of	severe	anxiety	for	3	days,	clozapine	was	prescribed	and	
increased.	Then	the	patient	presented	with	altered	mental	status	and	visual	
hallucinations.	Focal	SE	was	diagnosed	after	EEG.	Initial	imaging	was	non	
conclusive.	The	etiology	retained	using	the	SEEIT	was	related	to	the	
clozapine.	Later	MRI	revealed	a	PRES.	
Etiology	missed	on	CT	
9	 67	 F	 No	 Meningo-encephalitis	
(infectious)	
Cryptogenic	 Refractory	SE	and	fever	at	the	presentation.	Despite	a	mild	pleocytosis,	the	
CSF	remained	sterile.	The	pleocytosis	was	attributed	to	seizures.	
CSF	data	misinterpreted	
10	 75	 M	 No	 Cryptogenic	 HSV	1	encephalitis	 Because	of	fever	and	new	onset	SE,	the	SEEIT	suggested	a	CSF	analysis,	
which	was	normal	(4	WBC).	Later,	PCR	came	back	positive	for	HSV1.	LP	was	
performed	early	(ca.	36	hours	after	onset),	so	the	SEEIT	warned	against	
"false"	normal	CSF	in	early	phase	of	an	encephalitis.		
CSF	data	misinterpreted	
11	 46	 F	 Yes	 Sepsis	 Possible	posterior	reversible	
encephalopathy	syndrome	
(PRES)	
SE	in	the	context	of	sepsis	(pulmonary	origin)	and	known	epilepsy.	So,	using	
the	SEEIT,	sepsis	was	considered	as	a	provocative	factor.	Later	MRI	was	
consistent	with	a	PRES.	However	it	was	not	excluded	for	certain	that	the	MRI	
changes	were	due	to	seizures.	
Etiology	missed	on	CT	
12	 40	 F	 Yes	 Sepsis	 Known	epilepsy	without	
provocative	factors	
SE	in	the	context	of	fever,	systemic	inflammatory	response	syndrome	(SIRS)	
and	known	epilepsy.	So,	using	the	SEEIT,	sepsis	was	considered	as	a	
provocative	factor.	The	complete	evaluation	did	not	find	any	infectious	
source.	The	SIRS	was	attributed	to	the	SE	itself.			
SIRS	incorrectly	suspected	
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13	 54	 F	 No	 Acute	ischemic	stroke	 Brain	abscess	due	to	Bacillus	
Cereus	endocarditis	
Patient	known	for	acute	myeloid	leukemia.	Initial	CT	showed	a	probable	new	
ischemic	stroke.	Subsequent	MRI	revealed	an	abscess.	Endocarditis	was	
subsequently	found.	
Etiology	missed	on	CT	
14	 60	 M	 No	 Cryptogenic	 Alcohol	withdrawal	 Alcohol	withdrawal	was	denied	during	initial	assessment.	 Incomplete	history	
information	
15	 79	 M	 No	 Dementia	 Chronic	lymphocytic	leukemia	
with	CNS	infiltration	
Known	for	advanced	dementia	and	chronic	lymphocytic	leukemia.	Initial	
imaging	was	non	conclusive.	MRI	was	performed	4	days	later	and	showed	
focal	lesions	likely	due	to	infiltrative	lymphoma.	
Remote	brain	pathology	
incorrectly	retained	
16	 69	 F	 No	 Toxicometabolic	(in	
the	context	of	a	
known	CNS	B	
lymphoma)	
Microangiopathic	hemolytic	
anemia	
Initial	laboratory	testing	showed	renal	and	liver	impairments	of	unknown	
origin.	The	extensive	evaluation	revealed	a	microangiopathic	hemolytic	
anemia.	
Failure	to	identify	a	
complex	disease	in	the	
emergency	setting	
17	 71	 M	 No	 Meningo-encephalitis	
(infectious)	
Diffuse	large	B-cell	lymphoma	
with	CNS	infiltration	
Presented	with	SE	preceded	by	rapid	cognitive	decline.	CSF	showed	
pleocytosis	(728	white	cells/mm3).	CNS	infection	was	suspected.	Extensive	
evaluation	did	not	find	any	etiology.	A	malignant	edema	leaded	to	
herniation.	Autopsy	showed	a	diffuse	CNS	infiltration	by	large	B-cell	
lymphoma.	
CSF	data	misinterpreted	
18	 36	 M	 No	 Brain	lesion	of	unclear	
origin	
Cerebral	toxoplasmosis	 Known	for	HIV.	The	evaluation	in	the	emergency	department	identified	a	
newly	diagnosed	mass	without	clear	precision.	The	complete	evaluation	
revealed	a	cerebral	toxoplasmosis.	
Failure	to	identify	a	
complex	disease	in	the	
emergency	setting	
19	 76	 M	 No	 Cryptogenic	 Remote	subarachnoid	
hemorrhage	
The	previous	history	of	subarachnoid	hemorrhage	was	unknown	at	initial	
presentation.	
Incomplete	history	
information	
20	 68	 F	 No	 Toxic-metabolic	 Acute	ischemic	stroke	 Presented	with	several	mild	metabolic	disturbances	and	the	initial	CT	was	
considered	as	normal.	Subsequent	MRI,	advised	by	the	SEEIT	because	of	
focality	in	the	clinical	manifestation,	revealed	an	acute	stroke.		
Etiology	missed	on	CT	
21	 83	 F	 No	 Cryptogenic	 Acute	ischemic	stroke	 Initial	imaging	was	considered	as	normal.	Subsequent	MRI,	advised	by	the	
SEEIT	because	of	focality	in	the	clinical	manifestation,	revealed	an	acute	
ischemic	stroke.	
Etiology	missed	on	CT	
22	 79	 F	 No	 Drugs	intoxication	 Dementia	 Patient	had	mild	increase	in	anti-psychotic	treatment	in	setting	of	dementia	
and	very	mild	hypernatremia.	However,	the	features	identified	by	the	SEEIT	
were	not	considered	as	sufficient	to	provoke	SE.	
Disagreement	on	causality	
judgment	of	minor	
precipitants	
23	 49	 F	 Yes	 Known	epilepsy	
without	provocative	
factors	
ASD	related	 Patient	known	for	epilepsy	treated	with	LEV,	VPA	and	LCM.	There	was	no	
evidence	of	non-adherence	in	initial	evaluation.	Later,	low	level	of	VPA	level	
became	available	and	pointed	out	non-adherence.	
Incomplete	history	
information	
24	 27	 F	 No	 CNS	infection	 Cryptogenic	(NORSE)	 Presented	with	flu-like	symptoms	a	week	before	entering	a	prolonged	
refractory	non-convulsive	SE	in	coma.	The	CSF	in	early	phase	showed	a	mild	
lymphocytosis	(15	white	blood	cells	/	mm3).	Despite	a	very	broad	evaluation	
including	wide	infectious	and	autoimmune	panels,	no	etiology	was	found.	
She	left	the	hospital	74	days	later	with	significant	cognitive	problems.	
CSF	data	misinterpreted	
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Figure 1: The Status Epilepticus Etiology Identification Tool (SEEIT) 
Legend: The SEEIT tool as been designed to guide SE etiology assessment. It has to be 
used along with anti-seizure-drug protocol. Each point has to be assessed. 
Figure 2: Study profile 
Abbreviations: EEG: electroencephalogram; SE: status epilepticus; SEEIT: Status 
Epilepticus Etiology Identification Tool. 
 


